References
- Lyrica – Pregabalin – European Medicines Agency [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–426.
- Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213.
- Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491–496.
- Isoardi KZ, Polkinghorne G, Harris K, et al. Pregabalin poisoning and rising recreational use: a retrospective observational series. Br J Clin Pharmacol. 2020;86(12):2435–2440.
- Dufayet L, Monnet F, Laborde-Casterot H, et al. Unintentional exposure to pregabalin in ≤6-year-old children: a nationwide French Poison Control Center study. Clin Toxicol. 2020;2:1–7.
- Millar J, Sadasivan S, Weatherup N, et al. Lyrica nights-recreational pregabalin abuse in an urban emergency department. Emerg Med J. 2013;30(10):872–874.
- Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580–1589.
- Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study. J Anal Toxicol. 2019;43(7):564–570.